<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864953</url>
  </required_header>
  <id_info>
    <org_study_id>252LH301</org_study_id>
    <secondary_id>RPI 301</secondary_id>
    <secondary_id>2017-004854-41</secondary_id>
    <nct_id>NCT02864953</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction</brief_title>
  <acronym>CHARM</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of the investigational drug BIIB093 versus placebo in patients
      with a large hemispheric infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study, previously posted by Remedy Pharmaceuticals, Inc., has transitioned to Biogen
      with the acquisition of CIRARA.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 29, 2018</start_date>
  <completion_date type="Anticipated">June 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants with Improvement in Functional Outcome at Day 90 Assessed via the Modified Rankin Scale (mRS)</measure>
    <time_frame>Baseline up to Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to All-Cause Death</measure>
    <time_frame>Baseline up to Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Achieved mRS 0-4 at Day 90</measure>
    <time_frame>Baseline up to Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Midline Shift at 72 Hours</measure>
    <time_frame>Baseline up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">680</enrollment>
  <condition>Brain Edema</condition>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>BIIB093</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB093 administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB093</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>BIIB093</arm_group_label>
    <other_name>glibenclamide</other_name>
    <other_name>glibenclamide intravenous (IV)</other_name>
    <other_name>glyburide</other_name>
    <other_name>CIRARA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A clinical diagnosis of acute ischemic stroke in the middle cerebral artery (MCA)
             territory

          2. A large hemispheric infarction defined as; lesion volume of 80 to 300 centimeters
             cubed (cm^3) on magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI), or
             computed tomography perfusion (CTP), or an Alberta Stroke Program Early CT Score
             (ASPECTS) of 1 to 5 with involvement of at least 2 defined cortical regions

          3. Screening National Institutes of Health Stroke Scale (NIHSS) &gt;=10

          4. Study treatment infusion within 10 hours after time of symptom onset, if known, or the
             time last known normal

          5. For participants who receive thrombectomy, inclusion into the study must be based on
             post-thrombectomy MRI-DWI

        Exclusion Criteria:

          1. Participant is likely to have supportive care withdrawn on the first day

          2. Commitment to decompressive craniectomy (DC) prior to enrollment

          3. Evidence of concurrent infarction in the contralateral hemisphere sufficiently serious
             so as to affect functional outcome

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Medical Information</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Infarction</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Brain Edema Ischemia</keyword>
  <keyword>Pathological Processes Necrosis</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Glyburide</keyword>
  <keyword>Hypoglycemic Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Brain Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

